Printer Friendly

IVAX GETS FINAL FDA APPROVAL FOR TAMOXIFEN ANDA.

IVAX Corporation (AMEX:IVX)(LSE:IVX.L), Miami, Fla., has received final FDA approval for its Abbreviated New Drug Application (ANDA) for tamoxifen citrate tablets in 10 mg and 20 mg strengths. IVAX is now marketing tamoxifen citrate through its wholly owned subsidiary, IVAX Pharmaceuticals, Inc. Tamoxifen citrate is a nonsteroidal antiestrogen used in the treatment of breast cancer. It is the generic equivalent of AstraZeneca's Nolvadex(R). U.S. sales of branded and generic tamoxifen citrate were approximately $500 million in 2002.

IVAX currently has 37 ANDAs and one tentative approval pending at the FDA. The company is continuing its aggressive filing schedule for new ANDA submissions.

IVAX Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products in the U.S. and internationally.

For more information, call 305/575-6043
COPYRIGHT 2003 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Geographic Code:1USA
Date:Apr 1, 2003
Words:140
Previous Article:CURIS BMP-7 PROTEIN DRUG CANDIDATE ENHANCES STROKE RECOVERY.
Next Article:NYMOX BEGINS PHASE I STUDIES FOR NX-1207 PROSTATE TREATMENT.
Topics:


Related Articles
FDA GIVES TENTATIVE APPROVAL FOR GENERIC VERSION OF PROZAC.
IVAX GETS FINAL APPROVAL FOR GENERIC HYPERTENSION TABLETS.
IVAX GETS FINAL APPROVAL FOR METFORMIN.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |